Comparative Pharmacology
Head-to-head clinical analysis: BREYNA versus ENSKYCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREYNA versus ENSKYCE.
BREYNA vs ENSKYCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREYNA is a contraceptive vaginal ring that releases ethinyl estradiol and etonogestrel. Etonogestrel is a progestogen that inhibits ovulation by suppressing gonadotropin release. Ethinyl estradiol enhances the contraceptive effect by stabilizing the endometrium and increasing cervical mucus viscosity.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
1 mg subcutaneously twice daily
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
None Documented
None Documented
Terminal elimination half-life is 12 hours; in patients with moderate to severe renal impairment, half-life may be prolonged up to 24 hours, requiring dose adjustment
12 hours (terminal); allows once-daily dosing in most patients
Primarily renal excretion of unchanged drug (approximately 70%) and biliary/fecal elimination (approximately 30%)
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive